In patients with type 2 diabetes inadequately managed by diet and exercise alone, once-weekly semaglutide monotherapy significantly reduced HbA1c and body weight compared to placebo, demonstrating a promising safety profile, though with mild-to-moderate gastrointestinal side effects.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
CATEGORIES
© -2025 hormoneinsightc . all rights reserve.